

Pediatric Case Report and Overview of Autochthonous Tick-Borne Encephalitis, Belgium

Appendix

Additional serology and sequencing data

TBEV sequencing

Methods

Sample preparation and sequencing

RNA was extracted from a clinical serum sample, and the Sequence-Independent Single-Primer Amplification (SISPA) method was employed to increase the amount of genetic material for sequencing. SISPA includes a reverse transcription step that uses tagged random nine-base primers. The tag enables subsequent amplification with a primer complementary to the universal tag. The Twist Comprehensive Viral Research panel was then used to capture viral sequences. Following ONT adaptor ligation with the Ligation Sequencing Kit V14 (SQK-LSK114), the library was prepared for sequencing on a MinION R10.4 flow cell.

Data analysis and viral detection

Raw sequencing data was stored in FAST5 files and directly used as an input for our in-house viral metagenomics pipeline. In brief, FAST5 files were converted to FASTQ files by using Guppy and filtered based on quality and read length with Fastp. Reads mapped to the human genome by using Minimap2 were depleted. The remaining reads were mapped against a viral database with MetaMaps for viral taxonomic classification. The reference sequence of the matching viral taxon was then used to generate a consensus sequence by using Minimap2 followed by Medaka, iVar and homopolish.


Phylogenetic analysis

TBEV genomes (n = 58) were extracted from the NCBI Virus database (Appendix Table 1), with filters applied for Virus/Taxonomy (Tick-borne encephalitis virus taxid 11084), complete nucleotide sequences, and human as the host. This set of TBEV genomes was aligned by MAFFT (v 7.525) together with the consensus genome generated by our in-house pipeline. A maximum-likelihood (ML) phylogenetic tree was inferred from the alignment using IQ-TREE (v 2.3.6) with the MFP model, which automatically selects the best-fit substitution model using ModelFinder. Branch support for the ML phylogeny was assessed with 1000 standard non-parametric bootstrap analyses. Interactive tree of life (iTOL) was used to visualize the resulting tree.

Results

Viral detection


Our in-house viral metagenomics pipeline identified viral reads derived from the clinical sample matching solely to TBEV (n = 113492). The completeness of the generated consensus sequence was 52% with a vertical coverage of 5191 (Appendix Figure 1).



Appendix Figure 1. Coverage plot of TBEV reads identified in the sequence data from the clinical sample. On the x-axis every position of the TBEV reference genome with corresponding vertical coverage (depth) on the y-axis in log scale. Red vertical lines indicates gaps in the consensus genome.

Phylogenetic analysis

A phylogenetic approach was used to characterize the TBEV subtype of the virus detected in the clinical sample. The consensus genome clustered with European subtypes, indicating that the clinical sample contained the European subtype of TBEV (Appendix Figure 2).



Appendix Figure 2. Unrooted maximum likelihood phylogeny tree based on alignment of publicly available genome sequences (gray dots) and the consensus sequences derived from the clinical sample (white star). Clusters are annotated based on the TBEV subtype (Far-Eastern, European and Siberian).

Appendix Table 1. NCBI number of TBEV genomes extracted from NCBI virus platform including year of isolation and country. Subtypes are determined based on the tree results if not specified in the NCBI database

| NCBI ID | TBEV subtype | Country | Year of isolation |
|------------|--------------|----------------------------|-------------------|
| KJ922515.1 | European | Czech | NA |
| KJ922513.1 | European | Czech | NA |
| KJ922516.1 | European | Czech | NA |
| KJ922512.1 | European | Czech | NA |
| MG589937.1 | European | Finland | NA |
| OQ435379.1 | European | Estonia | 1987 |
| MT581212.1 | European | Sweden | 2019 |
| MK560446.1 | European | Russia | NA |
| MK562430.1 | European | Russia | 1967 |
| KU885457.1 | European | Russia | NA |
| KJ000002.1 | European | Russia | 1951 |
| KJ922514.1 | European | Czech | NA |
| GU121642.1 | Far-Eastern | Russia | 2008 |
| FJ402885.1 | Far-Eastern | Russia | 1985 |
| JQ650522.1 | Far-Eastern | People's Republic of China | 2001 |
| JQ650523.1 | Far-Eastern | People's Republic of China | 1953 |
| JF316708.1 | Far-Eastern | People's Republic of China | 2010 |
| JF316707.1 | Far-Eastern | People's Republic of China | 2010 |
| KJ739729.1 | Far-Eastern | Russia | 2008 |
| FJ997899.1 | Far-Eastern | Russia | 1990 |
| PP947713.1 | Far-Eastern | Russia | NA |
| PP708890.1 | Far-Eastern | Russia | 1999 |
| GQ228395.1 | Far-Eastern | Russia | 1997 |
| KU761567.1 | Far-Eastern | Russia | 1958 |
| KU761574.1 | Far-Eastern | Russia | 1958 |
| KU761572.1 | Far-Eastern | Russia | 1958 |
| KU761575.1 | Far-Eastern | Russia | 1958 |
| KU761569.1 | Far-Eastern | Russia | 1960 |
| FJ906622.1 | Far-Eastern | Russia | 1987 |
| KU761576.1 | Far-Eastern | Russia | 1937 |
| MT671300.1 | Far-Eastern | Russia | 1962 |
| KF951037.1 | Far-Eastern | Russia | 1966 |
| JF819648.2 | Far-Eastern | Russia | 1937 |
| MN115817.1 | Far-Eastern | Russia | 1969 |
| MT671301.1 | Far-Eastern | Russia | 1969 |
| MT671302.1 | Far-Eastern | Russia | 1957 |
| HQ901303.1 | Far-Eastern | Russia | 1992 |
| PP708887.1 | Far-Eastern | Russia | 1991 |
| HQ901367.1 | Far-Eastern | Russia | 2010 |
| HQ901366.1 | Far-Eastern | Russia | 2009 |
| FJ402886.1 | Far-Eastern | Russia | 1973 |
| PP937585.1 | Far-Eastern | Russia | 1991 |
| PP937586.1 | Far-Eastern | Russia | 1991 |
| PP937587.1 | Far-Eastern | Russia | 1992 |
| MG589939.1 | Siberian | Finland | 2015 |
| MN115819.1 | Siberian | Russia | 1964 |
| MN115820.1 | Siberian | Russia | 1966 |
| KC414090.1 | Siberian | Russia | 1999 |
| MT670183.1 | Siberian | Russia | 1963 |
| MN115818.1 | Siberian | Russia | 1965 |
| MT670184.1 | Siberian | Russia | 1966 |
| MH645612.1 | Siberian | Russia | 2003 |
| MN114635.1 | Siberian | Russia | 2018 |
| MF043955.1 | Siberian | Russia | NA |
| OQ565596.1 | Siberian | Russia | 2013 |
| MF043954.1 | Siberian | Russia | NA |
| KF644245.1 | Siberian | Russia | 2013 |
| MF043953.1 | Siberian | Russia | NA |

TBEV RT-PCR

TBEV RT-PCR was done using real-time reverse transcription PCR, adapted from (1).

Serology


TBEV-/JE-serology

Detection of TBEV-/JE-antibodies was performed using an immunofluorescence assay (Flavivirus Profile 2, Euroimmun AG, Lübeck, Germany).

Dengue serology

Detection of dengue IgM antibodies was performed with the Dengue Virus IgM Capture Dx Select (Focus Diagnostics, Cypress, CA, USA). Dengue IgG antibodies were detected with the Dengue Virus IgG Dx Select (Focus Diagnostics).

Belgian autochthonous Tick-Borne Encephalitis cases



Appendix Figure 3. Four autochthonous Tick-Borne Encephalitis cases in Belgium depicted on a geographic map of Belgium. We note no geographic link between our case (red star) and the previous 3 confirmed cases (black stars).

Reference

1. Stoefs A, Heyndrickx L, De Winter J, Coeckelbergh E, Willekens B, Alonso-Jiménez A, et al. Autochthonous cases of tick-borne encephalitis, Belgium, 2020. *Emerg Infect Dis.* 2021;27:2179–82. [PubMed](#)

Appendix Table 2. Additional details of autochthonous tick-borne encephalitis cases in a child in Belgium compared with 3 previous cases in adults*

| Characteristic | Patient no. from 2021 report (6) | | | Case report from 2024 (this study) |
|------------------------------|---|---|--------------|--|
| | 1 | 2 | 3 | |
| Travel history | None | None | None | Thailand, 3 wk before illness |
| Biphasic course | ND | ND | + | + |
| Signs/symptoms | | | | |
| Fever | + | + | + | + |
| Headache | – | + | + | + |
| Fatigue | + | + | – | + |
| Irritability | – | – | – | + |
| Meningeal signs | + | + | – | + |
| Disturbance of consciousness | + | + | – | – |
| Paresis | Facial palsy, brachial weakness | Motor polyradiculitis causing motor dysfunction | – | – |
| Myalgia | + | + | – | + |
| Cognitive impairment | + | – | – | – |
| Diarrhea | – | – | + | + |
| Tremor | + | – | – | – |
| Additional investigations | | | | |
| Laboratory findings† | ND | ND | ND | First phase: leukocytes, 1,800/μL; neutrophils, 680/μL; lymphocytes, 980/μL; platelets, 115,000/μL; CK, 423 U/L; CRP, <1 mg/L. Second phase: leukocytes, 20,500/μL; neutrophils, 15,590/μL; lymphocytes, 3,650/μL; platelets, 395,000/μL; CK, 51 U/L; CRP, <1 mg/L |
| Serology | ND | ND | ND | Negative for malaria, dengue, chikungunya, Zika, <i>Borrelia</i> , CMV, EBV, <i>Brucella</i> , <i>Leishmania</i> , <i>Leptospira</i> , JEV, WNV |
| Nasopharyngeal sample | ND | ND | ND | Negative for influenza A/B, COVID-19, RSV, adenovirus, enterovirus, metapneumovirus, parainfluenzavirus 1/2/3/4, <i>Legionella pneumophila</i> , <i>Chlamydomphila pneumoniae</i> , <i>Chlamydomphila psittaci</i> |
| Urine sample | ND | ND | ND | – |
| Stool sample | ND | ND | ND | Positive for <i>Salmonella enterica</i> serovar Bareilly, <i>Campylobacter jejuni</i> |
| Rheumatologic testing | ND | ND | ND | Negative for ANF, CTD screening |
| Imaging | Brain MRI: demyelinating lesions and encephalopathy | Negative MRI, PET | Negative PET | Negative abdominal ultrasound, bone scan, brain CT; brain MRI: aspecific enhancement of facial and vestibular nerves without clinical correlate |
| EEG | Diffuse slow activity | ND | ND | ND |
| Cardiac investigations | ND | ND | Negative TEE | Negative TEE |
| CSF leukocytes§ | 37 cells/μL | 371 cells/μL | ND | 106 cells/μL; lymphocytes, 69.8%; monocytes, 19.8%; segments, 10.4%; eosinophils, 0% |
| CSF protein§ | ND | ND | ND | 65 mg/dL |

*+, present/positive; –, absent/negative; ANF, antinuclear factor; CK, creatine kinase; CMV, cytomegalovirus; CRP, C-reactive protein; CSF, cerebrospinal fluid; CT, computed tomography; CTD, connective tissue disease; EBV, Epstein-Barr virus; EEG, electroencephalogram; MRI, magnetic resonance imaging; ND, not determined; PET, positron emission tomography; RSV, respiratory syncytial virus; TEE, transthoracic echocardiogram; TTE, transthoracic echocardiogram.

†To prevent an excess of data, only deviating and/or clinically relevant biochemical markers are listed. Reference values: leukocytes 4 500–13,500/μL; neutrophils, 1,500–8,000/μL; lymphocytes 1,500–6,800/μL; platelets, 164,000–369,000/μL; CK, 20–180 U/L; CRP, <5 mg/L; CSF leukocytes, 0–5/μL; CSF protein, 15–40 mg/dL